Resolution on Directed New Share Issue for the Creation of Equalization Shares (Item 6)
The Extraordinary General Meeting resolved through a directed new B share issue, increase the company's share capital by a maximum of 1,166338 SEK through the issuance of a maximum of 101 B-shares with a quota value of 0,0115479009105364 SEK at a subscription price of 0,0115479009105364 SEK per B-share (corresponding to the quota value). The total issue amount is maximum up to 1,166338 SEK.
The right to subscribe for the new B-shares shall belong to Nordic Issuing AB, 559338-2509, for further transfer and through Euroclear Sweden AB's arrangement, to such shareholders whose shareholdings are not evenly divisible by two hundred (200) for the implementation of the Board's concurrent proposal for consolidation of shares.
Resolution on Amendment of the Articles of Association (Item 7)
The Extraordinary General Meeting resolved on an amendment of the Articles of Association in accordance with the following:
*Please note that the changes only apply for the Swedish version of the Articles of Association.
+----------------------------------------+----------------------------------------+
|Current Wording                         |Proposed Wording                        |
+----------------------------------------+----------------------------------------+
|§ 4 Aktiekapital                        |§ 4 Aktiekapital                        |
|                                        |                                        |
|Aktiekapitalet skall utgöra lägst 15 000|Aktiekapitalet skall utgöra lägst 18 000|
|000 kronor och högst 60 000 000 kronor. |000 kronor och högst 72 000 000 kronor. |
+----------------------------------------+----------------------------------------+
|§ 5 Antal aktier                        |§ 5 Antal aktier                        |
|                                        |                                        |
|Antalet aktier skall vara lägst 700 000 |Antalet aktier skall vara lägst 7 800   |
|000 och högst 2 800 000 000 stycken.    |000 och högst 31 200 000 stycken.       |
+----------------------------------------+----------------------------------------+
Resolution on Consolidation of Shares (Item 8)
The Extraordinary General Meeting resolved, with the aim of achieving a more efficient number of shares for the company, to consolidate shares in a ratio of 200:1, meaning that 200 shares will be consolidated into 1 share. The Board is proposed to be authorized, until the fifth business day before the next Annual General Meeting at the latest, to determine the record date when the consolidation shall be executed and to take the other measures required to implement the consolidation.
The Decision entails that the company's share capital, after a decision on equalization share issue and consolidation, amounts to 18 134 146,882 913 SEK, distributed among 3000 A-shares and 7 848 707 B-shares, each with a quota value of 2,309580182107278 SEK.
Further information regarding the process of consolidation of the shares will be presented in a separated PM when the decisions above has been registered at the Swedish Companies Registration Office.
For more information, please contact:
Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
Website: www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
The information was submitted for publication through the agency of the contact person stated above on 12 April, 2024, at 14:45 CET
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se